Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Brisbane, CA, US. The stock last traded at $25.12, down 1.72% on the session, giving a market capitalisation of $988.1M. On trailing twelve-month figures it carries a trailing P/E of 71.34, a net margin of 2.0%. Its beta of 0.27 implies it has historically moved less than the broad market.
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Pacira BioSciences, Inc. is most often compared with the following Healthcare names: